Siping Central People's Hospital
Siping, Jilin, 136000, China
NCT Number: NCT07641101
This is a single-blind randomized controlled trial for patients with neurogenic bladder after incomplete spinal cord injury. Participants are randomly divided into two groups. The control group receives routine transitional nursing and telephone follow-up, while the intervention group gets 4-week app-supported transitional care including health education, bladder recording and online consultation. After intervention, bladder residual urine, urinary tract infection rate, self-care ability and quality of life are compared between two groups.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Siping, Jilin, 136000, China
Neurogenic bladder is a common complication after incomplete spinal cord injury, which easily leads to recurrent urinary tract infection and decreased quality of daily life. Traditional transitional follow-up is limited by time and space. This study adopts single-blind parallel-group RCT design. Eligible patients are randomly allocated at a 1:1 ratio. Control group receives standard inpatient nursing plus conventional post-discharge follow-up; intervention group receives identical inpatient care plus systematic app-based transitional care for 4 weeks. Primary outcomes are post-void residual urine volume and urinary tract infection incidence. Secondary outcomes contain self-care ability and quality of life assessed by standardized scales. All indicators are tested at baseline and 4 weeks after intervention to verify the clinical effect of app-assisted transitional nursing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosed with neurogenic bladder secondary to incomplete spinal cord injury; Age ranging from 18 to 75 years old; Clear consciousness, capable of cooperating with nursing assessment and mobile APP follow-up management; Voluntarily sign written informed consent. -
Exclusion criteria
Combined with severe renal insufficiency, malignant tumor or other life-threatening severe systemic diseases; History of previous bladder reconstructive surgery; Cognitive impairment unable to independently operate mobile APP; Refuse to continue follow-up or withdraw voluntarily during the research period.
-
Four-week continuous transitional nursing service via mobile APP for patients with neurogenic bladder after incomplete spinal cord injury, including disease-related health education, real-time voiding record, regular nursing reminder and online one-on-one nurse consultation, which differs from routine single telephone follow-up in control group.
routine standardized inpatient bladder nursing
Time frame: Within 4 weeks after subject enrollment
Count the occurrence of urinary tract infection within 4-week follow-up and calculate infection incidence of each group.
Time frame: Baseline and 4 weeks after intervention
Bladder residual urine volume is measured by ultrasonic examination at baseline and after 4 weeks of nursing intervention to compare the difference between two groups.
Time frame: Baseline and 4 weeks after intervention
Standardized scale scoring for self-care and quality of life before and after 4-week transitional nursing.
Xiamen University
Other
Effects Of App-Supported Transitional Care On Bladder Function And Quality Of Life in Patients With Neurogenic Bladder After Incomplete Spinal Cord Injury: A Randomised Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07507331
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT04350359
Central Nervous System Diseases, Female Urogenital Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04936217
Central Nervous System Diseases, Female Urogenital Diseases
Nîmes, Gard, France
View Trial DetailsNCT05380661
Anxiety Disorders, Anxiety State
Vancouver, British Columbia, Canada
View Trial Details